108 related articles for article (PubMed ID: 9165547)
1. Pharmacometric analysis of the effect of furosemide on suramin pharmacokinetics.
Piscitelli SC; Forrest A; Lush RM; Ryan N; Whitfield LR; Figg WD
Pharmacotherapy; 1997; 17(3):431-7. PubMed ID: 9165547
[TBL] [Abstract][Full Text] [Related]
2. Suramin: development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer.
Jodrell DI; Reyno LM; Sridhara R; Eisenberger MA; Tkaczuk KH; Zuhowski EG; Sinibaldi VJ; Novak MJ; Egorin MJ
J Clin Oncol; 1994 Jan; 12(1):166-75. PubMed ID: 8270974
[TBL] [Abstract][Full Text] [Related]
3. Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480.
Ahles TA; Herndon JE; Small EJ; Vogelzang NJ; Kornblith AB; Ratain MJ; Stadler W; Palchak D; Marshall ME; Wilding G; Petrylak D; Holland JC;
Cancer; 2004 Nov; 101(10):2202-8. PubMed ID: 15484217
[TBL] [Abstract][Full Text] [Related]
4. A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma.
Vogelzang NJ; Karrison T; Stadler WM; Garcia J; Cohn H; Kugler J; Troeger T; Giannone L; Arrieta R; Ratain MJ; Vokes EE
Cancer; 2004 Jan; 100(1):65-71. PubMed ID: 14692025
[TBL] [Abstract][Full Text] [Related]
5. Use of adaptive control with feedback to individualize suramin dosing.
Scher HI; Jodrell DI; Iversen JM; Curley T; Tong W; Egorin MJ; Forrest A
Cancer Res; 1992 Jan; 52(1):64-70. PubMed ID: 1727387
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of furosemide in patients on peritoneal dialysis.
Flinn A; Ledger S; Blake P
CANNT J; 2006; 16(3):40-4. PubMed ID: 17061696
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of low-dose suramin as a chemosensitizer in patients with advanced non-small cell lung cancer.
Villalona-Calero MA; Wientjes MG; Otterson GA; Kanter S; Young D; Murgo AJ; Fischer B; DeHoff C; Chen D; Yeh TK; Song S; Grever M; Au JL
Clin Cancer Res; 2003 Aug; 9(9):3303-11. PubMed ID: 12960116
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of suramin plus aminoglutethimide in two cohorts of patients with androgen-independent prostate cancer: simultaneous antiandrogen withdrawal and prior antiandrogen withdrawal.
Dawson N; Figg WD; Brawley OW; Bergan R; Cooper MR; Senderowicz A; Headlee D; Steinberg SM; Sutherland M; Patronas N; Sausville E; Linehan WM; Reed E; Sartor O
Clin Cancer Res; 1998 Jan; 4(1):37-44. PubMed ID: 9516950
[TBL] [Abstract][Full Text] [Related]
9. Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study.
Bok RA; Halabi S; Fei DT; Rodriquez CR; Hayes DF; Vogelzang NJ; Kantoff P; Shuman MA; Small EJ
Cancer Res; 2001 Mar; 61(6):2533-6. PubMed ID: 11289126
[TBL] [Abstract][Full Text] [Related]
10. Suramin, an active drug for prostate cancer: interim observations in a phase I trial.
Eisenberger MA; Reyno LM; Jodrell DI; Sinibaldi VJ; Tkaczuk KH; Sridhara R; Zuhowski EG; Lowitt MH; Jacobs SC; Egorin MJ
J Natl Cancer Inst; 1993 Apr; 85(8):611-21. PubMed ID: 8468719
[TBL] [Abstract][Full Text] [Related]
11. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects.
Licata G; Di Pasquale P; Parrinello G; Cardinale A; Scandurra A; Follone G; Argano C; Tuttolomondo A; Paterna S
Am Heart J; 2003 Mar; 145(3):459-66. PubMed ID: 12660669
[TBL] [Abstract][Full Text] [Related]
12. Comparison of 5-fluorouracil pharmacokinetics in whole blood, plasma, and red blood cells in patients with colorectal cancer.
Wattanatorn W; McLeod HL; Macklon F; Reid M; Kendle KE; Cassidy J
Pharmacotherapy; 1997; 17(5):881-6. PubMed ID: 9324177
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of furosemide regimens in neonates treated with extracorporeal membrane oxygenation.
van der Vorst MM; Wildschut E; Houmes RJ; Gischler SJ; Kist-van Holthe JE; Burggraaf J; van der Heijden AJ; Tibboel D
Crit Care; 2006; 10(6):R168. PubMed ID: 17140428
[TBL] [Abstract][Full Text] [Related]
14. A phase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer: toxicity and response.
Bowden CJ; Figg WD; Dawson NA; Sartor O; Bitton RJ; Weinberger MS; Headlee D; Reed E; Myers CE; Cooper MR
Cancer Chemother Pharmacol; 1996; 39(1-2):1-8. PubMed ID: 8995493
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics of the photodynamic therapy agent 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a in cancer patients.
Bellnier DA; Greco WR; Loewen GM; Nava H; Oseroff AR; Pandey RK; Tsuchida T; Dougherty TJ
Cancer Res; 2003 Apr; 63(8):1806-13. PubMed ID: 12702566
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer.
Rago RP; Einstein A; Lush R; Beer TM; Ko YJ; Henner WD; Bubley G; Merica EA; Garg V; Ette E; Harding MW; Dalton WS
Cancer Chemother Pharmacol; 2003 Apr; 51(4):297-305. PubMed ID: 12721757
[TBL] [Abstract][Full Text] [Related]
17. Nontoxic doses of suramin enhance activity of doxorubicin in prostate tumors.
Zhang Y; Song S; Yang F; Au JL; Wientjes MG
J Pharmacol Exp Ther; 2001 Nov; 299(2):426-33. PubMed ID: 11602651
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of biomarkers of survival response in hormone-refractory prostate cancer patients treated with suramin.
Sridhara R; Eisenberger MA; Sinibaldi VJ; Reyno LM; Egorin MJ
Cancer Epidemiol Biomarkers Prev; 1998 Jul; 7(7):631-4. PubMed ID: 9681533
[TBL] [Abstract][Full Text] [Related]
19. Use of suramin in treatment of prostatic carcinoma refractory to conventional hormonal manipulation.
LaRocca RV; Cooper MR; Uhrich M; Danesi R; Walther MM; Linehan WM; Myers CE
Urol Clin North Am; 1991 Feb; 18(1):123-9. PubMed ID: 1992566
[TBL] [Abstract][Full Text] [Related]
20. Furosemide does not improve renal recovery after hemofiltration for acute renal failure in critically ill patients: a double blind randomized controlled trial.
van der Voort PH; Boerma EC; Koopmans M; Zandberg M; de Ruiter J; Gerritsen RT; Egbers PH; Kingma WP; Kuiper MA
Crit Care Med; 2009 Feb; 37(2):533-8. PubMed ID: 19114909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
